OXYGEN, USP
Peakcarbon dioxide-air mixture
NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OXYGEN, USP (carbon dioxide-air mixture) is x-ray contrast activity [moa]. First approved in 2013.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXYGEN, USP is a carbon dioxide-air mixture administered via inhalation as a gas used for radiographic contrast imaging. It functions as an X-ray contrast agent to enhance visualization during diagnostic procedures. This product represents a niche respiratory diagnostic tool rather than a therapeutic agent.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30), suggesting stable but maturing commercial performance with limited team expansion opportunities.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate this is a legacy diagnostic product with minimal active hiring or career development momentum. Roles would typically be niche medical science, regulatory, or specialized sales positions in diagnostic imaging.
Diagnostic Product ManagerMedical Science Liaison (Imaging)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.